Cortez, 280 patient HCQ late treatment study: 15% lower mortality [p=1] https://c19p.org/cortez
copied to clipboard
Clinical characteristics and outcomes of COVID-19 patients in a tertiary hospital in Baguio City, Philippines
et al., Western Pacific Surveillance and Response Journal, doi:10.5365/wpsar.2021.12.4.852
Retrospective 280 hospitalized patients in the Philippines, 25 treated with HCQ, not showing any significant differences in unadjusted results.
|
risk of death, 15.0% lower, RR 0.85, p = 1.00, treatment 1 of 25 (4.0%), control 12 of 255 (4.7%), NNT 142.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Cortez et al., 11/11/2021, retrospective, Philippines, Asia, peer-reviewed, 29 authors, study period March 2020 - October 2020.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.